FINEOS
FINEOS Corporation (ASX:FCL ), the market-leading provider of group and individual core systems for life, accident and health insurance, today announced that it has executed a Heads of Agreement (HoA) with QInsure , a wholly owned subsidiary of the QSuper Group, one of Australia’s largest and most respected superannuation funds, which signals the intent to upgrade QInsure’s FINEOS Claims system to the FINEOS Claims SaaS edition on the FINEOS Platform, powered by AWS.
QInsure implemented and went live with FINEOS Claims in September 2019, which successfully delivered member-centric claims outcomes via improved, integrated and automated processes and workflow for claims covering life, Total and Permanent Disability (TPD) and Income Protection. Key highlights of the program included automatic payment calculations and the FINEOS Financial Services Council (FSC) Code of Practice business content that help case managers deliver on the insurance promise and meet regulatory obligations.
Speaking about the relationship, CEO of QInsure, Phil Fraser said, “Our partnership with FINEOS continues to grow and we are realising benefits from the FINEOS Claims system, including streamlined claims processes which enables our Claim Managers to focus on providing excellent outcomes to QSuper members. We are excited to continue our partnership with FINEOS to help support our organisation agility, digital customer experience and our service excellence.”
Mr Fraser added “While our partnership with FINEOS is relatively new, they have proven to be a reliable and valued partner. We will be working closely with FINEOS under this HoA to ensure APRA (the Australian Prudential Regulation Authority) is supportive of our approach.”
Michael Kelly , CEO, FINEOS concluded, “QInsure is a fantastic company to be in partnership with given their strong commitment to always doing the best by their members. We are excited about the next phase of our partnership with one of the most respected funds in Australia. The move to the FINEOS Platform is an exciting opportunity for FINEOS and our clients in the Australian and New Zealand region. Supporting this transition is a key strategic objective for FINEOS. Our North American clients have already adopted our SaaS based FINEOS Platform solutions over the past 3-4 years and we have been a ‘cloud only’ SaaS vendor in the US and Canada for over 3 years now.”
Last year FINEOS achieved record new sales of core solutions on the FINEOS Platform and we are seeing widespread interest in cloud solutions in Australia and New Zealand today. Covid-19 has accelerated Digital Transformation within the life, accident and health industry and carriers want to move to cloud computing in support of having flexible, modern business models which support working, buying and obtaining customer service that can be achieved from anywhere.
Over the past 6 years FINEOS has invested over €100m in R&D to develop FINEOS AdminSuite , an end-to-end SaaS core administration system for life, accident and health, including policy, billing and claims management. FINEOS listed on the ASX in 2019, and in August 2020 FINEOS acquired Limelight, a Silicon Valley SaaS provider of Quote, Underwrite and Rating software to the group and voluntary employee benefits industry in the US.
FINEOS enjoys established, trusted relationships with some of the largest and most respected carriers across the ANZ region. We pride ourselves on a very strong local team that has an enviable delivery and client support track record, and we are delighted to continue to work in partnership with QInsure.”
About FINEOS Corporation Limited
FINEOS is a leading provider of core systems for life, accident and health insurers globally with 6 of the largest life insurers in Australia as well as 7 of the 10 largest group life and health carriers in the US. With employees and offices throughout the world, FINEOS continues to scale rapidly, working with innovative progressive insurers in North America, Europe, and Asia Pacific.
The FINEOS Platform provides clients full end to end core insurance administration and includes the FINEOS AdminSuite core product suite as well as add-on products, FINEOS Engage to support digital engagement and FINEOS Insight for analytics and reporting.
For more information, visit www.FINEOS.com
About QInsure
QInsure was established to exclusively provide Group Life Insurance policies for QSuper, so life insurance benefits can be provided to QSuper members as part of their superannuation membership.
QInsure, the first insurance company set up by a superannuation fund in Australia, was established on 29 July 2015 as a wholly owned subsidiary of QSuper Limited and commenced issuing life insurance policies from 1 July 2016. The company has ASFL and APRA licenses to operate as an insurance company, as well as an independent Board of Directors and Executive Leadership Team.
About QSuper
QSuper started with an Act of Parliament in 1912 creating the entity now known as the QSuper Group.
Over time, QSuper expanded to become the superannuation fund for all current and former Queensland public sector employees and their spouses and is now Queensland’s largest super fund and one of the largest in Australia. QSuper has grown its range of products and services, with its customer base is now numbering more than 585,000 with over $113 billion in funds under administration.
With the passing of legislation in 2016 that removed the restrictions on who is eligible to join the Fund, from 1 July 2017 QSuper was able to welcome more Australians to experience the QSuper feeling.
For more information, visit https://qsuper.qld.gov.au/
View source version on businesswire.com: https://www.businesswire.com/news/home/20201020006052/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom